XML 23 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Available-for-sale securities      
Amortized Cost $ 203,512   $ 285,483
Gross Unrealized Gains 15   35
Gross Unrealized Losses (4)   (122)
Other Than Temporary Impairment Loss     (3,752)
Estimated Fair Value $ 203,523   281,644
Maturity period for marketable securities      
Maximum contractual maturity period 1 year    
Average contractual maturity period 3 months    
Proceeds from sale of available-for-sale securities $ 57,098 $ 5,000  
Theravance Biopharma      
Maturity period for marketable securities      
Gain on sale 1,200    
Issuer of available-for-securities other than Theravance Biopharma      
Maturity period for marketable securities      
Proceeds from sale of available-for-sale securities 49,400    
Cash and cash equivalents      
Available-for-sale securities      
Estimated Fair Value 76,077   95,090
Short-term marketable securities      
Available-for-sale securities      
Estimated Fair Value 127,446   143,698
Marketable securities      
Available-for-sale securities      
Estimated Fair Value 0   42,856
U.S. government securities      
Available-for-sale securities      
Amortized Cost 7,503   30,019
Gross Unrealized Gains 3   24
Gross Unrealized Losses 0   0
Other Than Temporary Impairment Loss     0
Estimated Fair Value 7,506   30,043
U.S. government agencies      
Available-for-sale securities      
Amortized Cost 69,965   34,756
Gross Unrealized Gains 9   6
Gross Unrealized Losses (2)   (12)
Other Than Temporary Impairment Loss     0
Estimated Fair Value 69,972   34,750
Corporate notes      
Available-for-sale securities      
Amortized Cost 27,485   80,880
Gross Unrealized Gains 3   5
Gross Unrealized Losses (2)   (110)
Other Than Temporary Impairment Loss     0
Estimated Fair Value 27,486   80,775
Commercial paper      
Available-for-sale securities      
Amortized Cost 54,702   34,469
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Other Than Temporary Impairment Loss     0
Estimated Fair Value 54,702   34,469
Ordinary shares of Theravance Biopharma      
Available-for-sale securities      
Amortized Cost     10,269
Gross Unrealized Gains     0
Gross Unrealized Losses     0
Other Than Temporary Impairment Loss     (3,752)
Estimated Fair Value     6,517
Money market funds      
Available-for-sale securities      
Amortized Cost 43,857   95,090
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Other Than Temporary Impairment Loss     0
Estimated Fair Value $ 43,857   $ 95,090